Caffeine for Apnea of Prematurity

Caffeine for Apnea of Prematurity

Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an immature central nervous system. It is also used frequently in these infants to facilitate weaning f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2006-05, Vol.354 (20), p.2179-2181
1. Verfasser: Bancalari, Eduardo
Format: Artikel
Sprache:eng
Schlagworte:
Apnea - drug therapy
Bronchopulmonary Dysplasia - prevention & control
Caffeine - therapeutic use
Central Nervous System Stimulants - therapeutic use
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - drug therapy
Infant, Very Low Birth Weight
Respiration, Artificial
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2181
container_issue 20
container_start_page 2179
container_title The New England journal of medicine
container_volume 354
creator Bancalari, Eduardo
description Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an immature central nervous system. It is also used frequently in these infants to facilitate weaning from mechanical ventilation. Despite the widespread use of caffeine for these indications, the evidence to support its use is based on the results of a few relatively small and short-term studies. 1 Information is lacking on possible long-term effects of prolonged administration of caffeine on the development of the brain and other organs. In this . . .
doi_str_mv 10.1056/NEJMe068028
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67984592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67984592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-32b807fd06892e78fdd31b1309125a247446e5cc5922d2c28031da1e10b6bb783</originalsourceid><addsrcrecordid>eNptkEtLw0AURgdRbK2u3EtEcCPRec9kWUJ9UR8LXQ-T5A6kdJI6kyz67x1pQRfezYXL-T4uB6Fzgm8JFvLudfH8AlhqTPUBmhLBWM45lodoitMp56pgE3QS4wqnIbw4RhMiFVZKyCm6LK1z0HaQuT5k800HNutd9h7A22EM7bA9RUfOriOc7fcMfd4vPsrHfPn28FTOl3nNBB9yRiuNlWvSIwUFpV3TMFIRhgtChaVccS5B1LUoKG1oTTVmpLEECK5kVSnNZuh617sJ_dcIcTC-jTWs17aDfoxGqkLzlE7gzQ6sQx9jAGc2ofU2bA3B5seI-WMk0Rf72rHy0PyyewUJuNoB3kfTwcr_W_MNEr5jPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67984592</pqid></control><display><type>article</type><title>Caffeine for Apnea of Prematurity</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Bancalari, Eduardo</creator><creatorcontrib>Bancalari, Eduardo</creatorcontrib><description>Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an immature central nervous system. It is also used frequently in these infants to facilitate weaning from mechanical ventilation. Despite the widespread use of caffeine for these indications, the evidence to support its use is based on the results of a few relatively small and short-term studies. 1 Information is lacking on possible long-term effects of prolonged administration of caffeine on the development of the brain and other organs. In this . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe068028</identifier><identifier>PMID: 16707756</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Apnea - drug therapy ; Bronchopulmonary Dysplasia - prevention &amp; control ; Caffeine - therapeutic use ; Central Nervous System Stimulants - therapeutic use ; Humans ; Infant, Newborn ; Infant, Premature ; Infant, Premature, Diseases - drug therapy ; Infant, Very Low Birth Weight ; Respiration, Artificial</subject><ispartof>The New England journal of medicine, 2006-05, Vol.354 (20), p.2179-2181</ispartof><rights>Copyright © 2006 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-32b807fd06892e78fdd31b1309125a247446e5cc5922d2c28031da1e10b6bb783</citedby><cites>FETCH-LOGICAL-c354t-32b807fd06892e78fdd31b1309125a247446e5cc5922d2c28031da1e10b6bb783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe068028$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe068028$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52361,54043,64364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16707756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bancalari, Eduardo</creatorcontrib><title>Caffeine for Apnea of Prematurity</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an immature central nervous system. It is also used frequently in these infants to facilitate weaning from mechanical ventilation. Despite the widespread use of caffeine for these indications, the evidence to support its use is based on the results of a few relatively small and short-term studies. 1 Information is lacking on possible long-term effects of prolonged administration of caffeine on the development of the brain and other organs. In this . . .</description><subject>Apnea - drug therapy</subject><subject>Bronchopulmonary Dysplasia - prevention &amp; control</subject><subject>Caffeine - therapeutic use</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Premature</subject><subject>Infant, Premature, Diseases - drug therapy</subject><subject>Infant, Very Low Birth Weight</subject><subject>Respiration, Artificial</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtLw0AURgdRbK2u3EtEcCPRec9kWUJ9UR8LXQ-T5A6kdJI6kyz67x1pQRfezYXL-T4uB6Fzgm8JFvLudfH8AlhqTPUBmhLBWM45lodoitMp56pgE3QS4wqnIbw4RhMiFVZKyCm6LK1z0HaQuT5k800HNutd9h7A22EM7bA9RUfOriOc7fcMfd4vPsrHfPn28FTOl3nNBB9yRiuNlWvSIwUFpV3TMFIRhgtChaVccS5B1LUoKG1oTTVmpLEECK5kVSnNZuh617sJ_dcIcTC-jTWs17aDfoxGqkLzlE7gzQ6sQx9jAGc2ofU2bA3B5seI-WMk0Rf72rHy0PyyewUJuNoB3kfTwcr_W_MNEr5jPA</recordid><startdate>20060518</startdate><enddate>20060518</enddate><creator>Bancalari, Eduardo</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060518</creationdate><title>Caffeine for Apnea of Prematurity</title><author>Bancalari, Eduardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-32b807fd06892e78fdd31b1309125a247446e5cc5922d2c28031da1e10b6bb783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Apnea - drug therapy</topic><topic>Bronchopulmonary Dysplasia - prevention &amp; control</topic><topic>Caffeine - therapeutic use</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Premature</topic><topic>Infant, Premature, Diseases - drug therapy</topic><topic>Infant, Very Low Birth Weight</topic><topic>Respiration, Artificial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bancalari, Eduardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bancalari, Eduardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Caffeine for Apnea of Prematurity</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2006-05-18</date><risdate>2006</risdate><volume>354</volume><issue>20</issue><spage>2179</spage><epage>2181</epage><pages>2179-2181</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an immature central nervous system. It is also used frequently in these infants to facilitate weaning from mechanical ventilation. Despite the widespread use of caffeine for these indications, the evidence to support its use is based on the results of a few relatively small and short-term studies. 1 Information is lacking on possible long-term effects of prolonged administration of caffeine on the development of the brain and other organs. In this . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16707756</pmid><doi>10.1056/NEJMe068028</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-4793
ispartof The New England journal of medicine, 2006-05, Vol.354 (20), p.2179-2181
issn 0028-4793
1533-4406
language eng
recordid cdi_proquest_miscellaneous_67984592
source MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine
subjects Apnea - drug therapy
Bronchopulmonary Dysplasia - prevention & control
Caffeine - therapeutic use
Central Nervous System Stimulants - therapeutic use
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - drug therapy
Infant, Very Low Birth Weight
Respiration, Artificial
title Caffeine for Apnea of Prematurity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T10%3A02%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Caffeine%20for%20Apnea%20of%20Prematurity&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bancalari,%20Eduardo&rft.date=2006-05-18&rft.volume=354&rft.issue=20&rft.spage=2179&rft.epage=2181&rft.pages=2179-2181&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe068028&rft_dat=%3Cproquest_cross%3E67984592%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67984592&rft_id=info:pmid/16707756&rfr_iscdi=true